TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases — Stella

View on ClinicalTrials.gov

Recruiting

Back to NSCLC trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality

Key details

Phase

Safety & dosing

Sponsor

TYK Medicines, Inc

Enrollment target

~420 participants

Started

August 2023

Primary completion

June 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 80 Years

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.